January 30th 2023
Results from the phase 1/2 CodeBreaK 100 trial indicate that sotorasib yields positive anticancer activity and safety in patients with pancreatic cancer harboring KRAS p.G12C mutations.
January 21st 2023
FDA Approves New Dosing Regimens, Indications for Capecitabine Across Multiple Cancer TypesDecember 15th 2022
The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.
Irinotecan Liposome Injection Plus NALIRIFOX Meets Primary End Point for Most Common Type of Pancreatic CancerNovember 9th 2022
Patients with metastatic pancreatic ductal adenocarcinoma—the most common type of pancreatic cancer—may benefit from treatment with irinotecan liposome injection in combination with fluorouracil/leucovorin and oxaliplatin, according to findings from the phase 3 NAPOLI3 trial.
Radionucleotide 177Lu-Edotreotide Receives Fast Track Designation From the FDA for GEP-NETsOctober 27th 2022
Patients with gastroenteropancreatic neuroendocrine tumors may benefit from treatment with radionucleotide therapeutic 177Lu-edotreotide, which received fast track designation from the FDA.
SBRT Plus Nivolumab/Ipilimumab Yields Meaningful Activity in Metastatic Pancreatic CancerOctober 21st 2022
Results from the phase 2 CheckPAC trial indicated that stereotactic body radiotherapy plus nivolumab and ipilimumab produced a promising clinical benefit rate for patients with refractory metastatic pancreatic cancer.
Perioperative/Adjuvant Only Gemcitabine/Nab-Paclitaxel Misses Mark in Resectable PDACOctober 20th 2022
Disease-free survival was not reached with perioperative nor adjuvant chemotherapy with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer, although neoadjuvant chemotherapy yielded a numerical improvement in overall survival, according to data from the phase 2 NEONAX trial.
SY-5609 Receives Orphan Drug Designation From FDA in Relapsed Metastatic Pancreatic CancerSeptember 19th 2022
An ongoing phase 1 trial is assessing the potential of SY-5609 plus chemotherapy in patients with advanced solid tumors, with the FDA granting orphan drug designation to the combination for patients with relapsed metastatic pancreatic cancer.
Pamela L. Kunz, MD, on Temozolomide Plus Capecitabine in Advanced Pancreatic Neuroendocrine TumorsSeptember 8th 2022
Results from a phase 2 trial of temozolomide or temozolomide plus capecitabine showed promising efficacy of the regimens for patients with advanced pancreatic neuroendocrine tumors.
First-Line FOLFIRINOX and Gemcitabine/Nab-Paclitaxel Show Comparable Survival in Advanced PDACSeptember 2nd 2022
Results from a phase 3 trial show similar results in regard to overall survival when patients with advanced pancreatic ductal adenocarcinoma were treated with either folinic acid, fluorouracil, irinotecan, oxaliplatin or gemcitabine/nab-paclitaxel in the first line.
Niraparib Plus Ipilimumab Yields Enhanced 6-Month PFS vs Niraparib Plus Nivolumab in Advanced Pancreatic CancerJuly 31st 2022
Results from a phase 1b/2 trial indicated that niraparib plus nivolumab yielded superior progression-free survival at 6 months vs niraparib and ipilimumab for patients with platinum-sensitive advanced pancreatic cancer.
Neoadjuvant mFOLFIRINOX Alone Yields Favorable Survival in Borderline Resectable PDACJuly 28th 2022
Patients with borderline resectable pancreatic ductal adenocarcinoma experienced favorable overall survival following treatment with mFOLFIRINOX alone, with additional hypofractionated radiotherapy showing little benefit.
Atezolizumab Plus Bevacizumab Induces Promising Clinical Responses in Neuroendocrine TumorsJuly 19th 2022
Patients with pancreatic and extrapancreatic neuroendocrine tumors treated with atezolizumab plus bevacizumab experienced consistent clinical responses and a progression-free survival consistent with other therapies.
Robert H. Vonderheide, MD, DPhil, Discusses Genomic Correlates of Response to Chemoimmunotherapy in PDACJuly 18th 2022
Biosignatures data from the PRINCE trial show sophisticated precision approaches may be necessary to optimize chemoimmunotherapy use in pancreatic ductal adenocarcinoma.
Investigators Uncover PDAC Biosignatures Linked With Better Responses to ChemoimmunotherapyJuly 13th 2022
At the 2022 American Society of Clinical Oncology Annual meeting, Robert H. Vonderheide, MD, DPhil, and colleagues from the Parker Institute for Cancer Immunotherapy present research into biosignatures of survival with different chemoimmunotherapy regimens for pancreatic ductal adenocarcinoma.
Addition of Nimotuzumab to Chemotherapy Increases OS in KRAS Wild-Type Advanced Pancreatic CancerJune 3rd 2022
Nimotuzumab plus gemcitabine improved overall survival in patients with KRAS wild-type advanced pancreatic cancer, especially in those who did not need surgery for obstruction of a pancreatic bile duct.
SBRT Plus Pembrolizumab and Trametinib May Become a Promising Treatment Option in Locally Recurrent Pancreatic CancerMay 11th 2022
Stereotactic body radiotherapy plus pembrolizumab and trametinib could potentially become a novel treatment strategy for patients with locally recurrent pancreatic cancer following surgery.
Sintilimab Improved Response Rates for Metastatic or Recurrent Pancreatic AdenocarcinomaJanuary 21st 2022
Although sintilimab improved overall response rates and maintained a tolerable safety profile for patients with metastatic or recurrent pancreatic adenocarcinoma, it did not improve overall or progression-free survival.
High Rates of Disease Control Derived in Pretreated PDAC and Other GI Malignancies With Adagrasib MonotherapyJanuary 21st 2022
Updated results from a cohort of the KRYSTAL-1 trial spotlight the potential of adagrasib for patients with previously treated KRAS G12C¬–mutant gastrointestinal tumors.
Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma
Molecular profiling is being explored in pancreatic adenocarcinoma as a tool to assist with early detection, prognosis, and patient selection in targeted therapy clinical trials.
Diane Simeone, MD, Champions Early Detection of Pancreatic Cancer Through the PRECEDE ConsortiumNovember 25th 2021
Diane Simeone, MD, spoke to the need to determine which patients are at risk of developing pancreatic cancer, the importance of early detection, and challenges that need to be addressed in order to improve survival.
Hidalgo Medina, MD, PhD, Discusses the Use of Motixafortide/Pembrolizumab and FOLFIRI in PDACNovember 24th 2021
For Pancretic Cancer Awareness month, CancerNetwork® spoke with Manuel Hidalgo Medina, MD, PhD, about the importance of the phase 2 COMBAT/KEYNOTE-202 trial examining motixafortide and pembrolizumab plus nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic ductal adenocarcinoma.
Andrew Hendifar, MD, on Developing Targeted Approaches in Pancreatic CancersNovember 19th 2021
In an interview with CancerNetwork®, Andrew Hendifar, MD discusses a case series analysis focused on real-world outcomes with targeted and standard therapies in a subset of patients with pancreatic cancer and RAF alterations.
Using Genetic Predispositions to Determine the Likelihood of Being Diagnosed With Pancreatic CancerNovember 1st 2021
For Pancreatic Cancer Awareness Month, CancerNetwork® spoke with Allyson Ocean, MD, about how family members of patients with pancreatic cancer should seek genetic testing to determine if they are predisposed to pancreatic cancer.
Eryaspase Plus Chemotherapy Did Not Significantly Improve OS in Second-Line Advanced Pancreatic Cancer but Yielded Superior Disease ControlOctober 29th 2021
Patients treated with eryaspase for second line advanced pancreatic cancer did not meet the primary end point of overall survival in the TRYbeCA-1 trial.